Veradermics (MANE) Financials: Revenue & Earnings
MANE$145.37+1.54 +1.07%
$6.07B
Market Cap
-51.74
P/E
30.16
Forward P/E
47
Score
Veradermics (MANE) Financials: Revenue & Earnings
MANE price $145.37 +1.54 +1.07%
- Ticker
- MANE
- Price
- $145.37
- Change
- +1.54 +1.07%
- Market cap ?
- $6.07B
- P/E ?
- -51.74
- Forward P/E ?
- 30.16
- Dividend yield ?
- 0.00%
- Beta ?
- 1.23
- Sector
- Healthcare
- Industry
- Biotechnology
- Stocklytics score
- 47
- Value
- 30
- Quality
- 49
- Growth
- 63
Stocklytics score rationale: value 30, quality 49, growth 63.
Financials
| 2023 | 2024 | 2025 |
|---|---|---|
| 0 | 0 | 0 |
Veradermics, Incorporated functions as a biopharmaceutical enterprise focused on devising pioneering therapeutic interventions for various skin and cosmetic disorders. The company's development pipeline includes treatments for Pattern Hair Loss (PHL), impacting both adult and pediatric demographics. A flagship offering is VDPHL01, an orally administered, non-hormonal medication specifically for chronic hair loss…
Earnings and financials
Veradermics, Incorporated (MANE) trades at $145.37, with a market cap of $6.07B and a trailing P/E of -51.74. Revenue below is the annual history on file. It describes what the business has already reported. It is not a forecast and it is not a recommendation.
Financials
| 2023 | 2024 | 2025 |
|---|---|---|
| 0 | 0 | 0 |
Insights · Dividends · Forecast · Financials · Learn